Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,. Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.
In FY 2024-25, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively.
Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, ...2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/- each have been allotted and issued.
At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated R&D houses, spread across the globe.
Company completed execution of high-value projects across Biologics, Injectables, and Oral Technologies in FY 2025.
FAQs on OneSource Specialty Pharma Ltd
1. Can I buy OneSource Specialty Pharma Ltd from PL Capital? ›
Yes, you can invest in OneSource Specialty Pharma Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track OneSource Specialty Pharma Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade OneSource Specialty Pharma Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.
2. Does OneSource Specialty Pharma Ltd pay dividends? ›
OneSource Specialty Pharma Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.
3. What is the current share price of OneSource Specialty Pharma Ltd ? ›
As of
01-Jan-1980 , 00:00:00 the share price for OneSource Specialty Pharma Ltd. is ₹ 1119.9 on the NSE (Note: Prices are dynamic and update frequently during market hours).
4. What is the 52-week high and low of OneSource Specialty Pharma Ltd ? ›
The 52-week high and low of OneSource Specialty Pharma Ltd share price is ₹ - ₹ as of
01-Jan-1980 , 00:00:00 .
